The FDA and American Regent have notified healthcare professionals of a voluntary nationwide recall of all lots of its ketorolac tromethamine injection 30mg/mL.

Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.

American Regent is recalling all lots of Ketorolac Tromethamine Injection, USP, 15 mg/mL, 1mL single dose vial, with the NDC number 0517-0601-25. The product is used to treat moderate to severe ...

A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for ...

[226 + Pages Research Study] According to a market research study published by Zion Market Research, the demand analysis of Global Carboprost Tromethamine Market size & share revenue was valued at ...

The global carboprost tromethamine market size is anticipated to grow from USD 2 billion to USD 2.96 billion in 10 years. The market will experience rapid growth due to the increasing healthcare ...

Ketorolac Tromethamine Injection USP has an estimated market size of US$ 59 million for twelve months ending June 2022 according to IQVIA. ETHealthWorld Published On Nov 3, 2022 at 03:25 PM IST ...

Carboprost Tromethamine is a generic therapeutic equivalent version of (RLD), HEMABATE Injection, of Pfizer Inc. Carboprost Tromethamine is used to treat severe bleeding after childbirth (postpartum).

According to IQVIA data, Ketorolac Tromethamine Injection USP has an estimated market size of USD 59 million in the US. PTI first published: Nov 3, 2022 01:15 pm ...

Alembic has received the Food and Drug Administration’s nod for ketorolac tromethamine injection, 15 mg/ml, 30 mg/ml, and 30 mg/ml single-dose vials. The drug is the generic of Toradol, which is ...